These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12658372)

  • 1. Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat.
    Treseder SA; Rose S; Summo L; Jenner P
    J Neural Transm (Vienna); 2003 Mar; 110(3):229-38. PubMed ID: 12658372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
    Treseder SA; Rose S; Jenner P
    Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatic L-amino acid decarboxylase (AAAD) activity in rhesus macaque striatum after MAO-B inhibition by Ro 16-6491.
    DeJesus OT; Flores LG; Roberts AD; Dick DW; Bartlett RM; Murali D; Nickles RJ
    Synapse; 2005 Apr; 56(1):54-6. PubMed ID: 15700282
    [No Abstract]   [Full Text] [Related]  

  • 4. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins.
    Carotti A; Altomare C; Catto M; Gnerre C; Summo L; De Marco A; Rose S; Jenner P; Testa B
    Chem Biodivers; 2006 Feb; 3(2):134-49. PubMed ID: 17193252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-beta-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase.
    Palfreyman MG; McDonald IA; Fozard JR; Mely Y; Sleight AJ; Zreika M; Wagner J; Bey P; Lewis PJ
    J Neurochem; 1985 Dec; 45(6):1850-60. PubMed ID: 3840523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine.
    Berry MD; Scarr E; Zhu MY; Paterson IA; Juorio AV
    Br J Pharmacol; 1994 Dec; 113(4):1159-66. PubMed ID: 7889269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of benserazide on changes in monoamine oxidase activity in some rat tissues following treatment with L-DOPA.
    Callingham BA; Lyles GA
    J Auton Pharmacol; 1980 Nov; 1(1):9-16. PubMed ID: 7341636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of aromatic L-amino acid decarboxylase under physiological conditions: optimization of 3-hydroxybenzylhydrazine concentration to prevent concurrent inhibition of monoamine oxidase.
    Hunter LW; Rorie DK; Tyce GM
    Biochem Pharmacol; 1993 Mar; 45(6):1363-6. PubMed ID: 8096696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of Dopamine by Aromatic l-Amino Acid Decarboxylase Cells after Spinal Cord Injury.
    Ren LQ; Wienecke J; Hultborn H; Zhang M
    J Neurotrauma; 2016 Jun; 33(12):1150-60. PubMed ID: 26830512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
    Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
    Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microdialysis with radiometric monitoring of L-[β-11C]DOPA to assess dopaminergic metabolism: effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate.
    Okada M; Nakao R; Hosoi R; Zhang MR; Fukumura T; Suzuki K; Inoue O
    J Cereb Blood Flow Metab; 2011 Jan; 31(1):124-31. PubMed ID: 20407462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of some decarboxylase inhibitors on striatal tyramines in the mouse.
    Juorio AV
    Neuropharmacology; 1983 Jan; 22(1):71-3. PubMed ID: 6843786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of decarboxylase inhibitors on brain p-tyrosine levels.
    Dyck LE
    Biochem Pharmacol; 1987 Apr; 36(8):1373-6. PubMed ID: 2885004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
    Finberg JP; Gross A; Bar-Am O; Friedman R; Loboda Y; Youdim MB
    Br J Pharmacol; 2006 Nov; 149(6):647-56. PubMed ID: 17016505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
    Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.